United Therapeutics (UTHR) Capital Expenditures (2009 - 2026)

United Therapeutics has disclosed Capital Expenditures across 18 years of filings, most recently posting $100.8 million for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $100.8 million, up 113.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $169.9 million (up 270.96% YoY), and the FY2025 annual result was $116.3 million, up 423.87% from the prior year.
• Capital Expenditures came in at $100.8 million for Q1 2026 at United Therapeutics, up from $24.1 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $141.9 million in Q3 2024 to a low of -$137.6 million in Q4 2024.
• The 5-year median for Capital Expenditures is $41.3 million (2023), against an average of $35.8 million.
• Across the five-year window, Capital Expenditures slumped 274.84% in 2024 and jumped 1677.19% in 2025, its largest moves.
• United Therapeutics' Capital Expenditures stood at $39.5 million in 2022, then surged by 99.24% to $78.7 million in 2023, then plunged by 274.84% to -$137.6 million in 2024, then surged by 117.51% to $24.1 million in 2025, then jumped by 318.26% to $100.8 million in 2026.
• The last three Capital Expenditures figures came in at $100.8 million (Q1 2026), $24.1 million (Q4 2025), and -$44.9 million (Q3 2025), per Business Quant data.